RECRUITING

Investigating the Effect of Topical Imiquimod on Sebaceous Hyperplasia

Conditions

Sebaceous Hyperplasia Lesions on both sides of the face Topical imiquimod

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study is being completed to determine if 8 weeks of treatment with imiquimod can shrink sebaceous hyperplasia.

Official Title

Investigating the Effect of Topical Imiquimod on Sebaceous Hyperplasia

Quick Facts

Study Start:2025-03-11

Study Completion:2027-09-11

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06840470

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Patient has sebaceous hyperplasia lesions on both sides of the face. At least one sebaceous hyperplasia lesion on each side of the face is 1 mm or more in size. * If of child-bearing potential, subject agrees to the use of highly effective contraception during study participation. For women of childbearing potential, acceptable pregnancy prevention measures will include abstinence, barrier methods, chemical methods, or surgical. * Ability to understand and willingness to sign a written informed consent	* Current use or prior use of a retinoid (e.g. tretinoin) within the last 4 weeks. * Prior use of imiquimod on the treated area. * Concurrent use of 5-fluorouracil, aminolevulinic acid (photodynamic therapy), or psoralen therapy, or use of any of these within the last 4 weeks. * Concurrent facial peels or cosmetic laser therapy on the treated areas. * Nursing, pregnant or planning to become pregnant. * Immunocompromised status (e.g. organ transplantation recipients or patients on cyclosporine). * Current participation in other investigational trials. * Known or suspected history of a clinically significant systemic disease (e.g., immunological deficiencies), unstable medical disorders (e.g., unstable diabetes), life-threatening disease or current malignancies. * Known hypersensitivity to any of the following (in any dosage form): imiquimod or any component of the study medications. * Received radiation therapy and/or anti-neoplastic agents within 3 months prior to study entry.

Inclusion Criteria

Exclusion Criteria

* Patient has sebaceous hyperplasia lesions on both sides of the face. At least one sebaceous hyperplasia lesion on each side of the face is 1 mm or more in size.
* If of child-bearing potential, subject agrees to the use of highly effective contraception during study participation. For women of childbearing potential, acceptable pregnancy prevention measures will include abstinence, barrier methods, chemical methods, or surgical.
* Ability to understand and willingness to sign a written informed consent

* Current use or prior use of a retinoid (e.g. tretinoin) within the last 4 weeks.
* Prior use of imiquimod on the treated area.
* Concurrent use of 5-fluorouracil, aminolevulinic acid (photodynamic therapy), or psoralen therapy, or use of any of these within the last 4 weeks.
* Concurrent facial peels or cosmetic laser therapy on the treated areas.
* Nursing, pregnant or planning to become pregnant.
* Immunocompromised status (e.g. organ transplantation recipients or patients on cyclosporine).
* Current participation in other investigational trials.
* Known or suspected history of a clinically significant systemic disease (e.g., immunological deficiencies), unstable medical disorders (e.g., unstable diabetes), life-threatening disease or current malignancies.
* Known hypersensitivity to any of the following (in any dosage form): imiquimod or any component of the study medications.
* Received radiation therapy and/or anti-neoplastic agents within 3 months prior to study entry.

Contacts and Locations

Study Contact

Joseph Durgin, MD, MSc

CONTACT

734-936-4054

durginj@umich.edu

Mio Nakamura, MD

CONTACT

734-936-4054

mionak@med.umich.edu

Principal Investigator

Sunny Wong, PhD

PRINCIPAL_INVESTIGATOR

University of Michigan

Study Locations (Sites)

University of Michigan

Ann Arbor, Michigan, 48109

United States

Collaborators and Investigators

Sponsor: University of Michigan

Sunny Wong, PhD, PRINCIPAL_INVESTIGATOR, University of Michigan

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-03-11

Study Completion Date2027-09-11

Study Record Updates

Study Start Date2025-03-11

Study Completion Date2027-09-11

Terms related to this study

Keywords Provided by Researchers

Lesions on both sides of the face
Topical imiquimod

Additional Relevant MeSH Terms

Sebaceous Hyperplasia